Healthcare

Orion Group Half-Year Financial Report January–June 2026

ORION CORPORATION HALF-YEAR FINANCIAL REPORT 1–6/2026 17 JULY 2026 at 12:00 EEST Orion Group Half-Year Financial Report January–June 2026 April–June 2026 Highlights Net sales totalled EUR 521.6 (April–June 2025: 416.5) million Operating profit was EUR 176.6 (104.6) millionBasic earnings per share were EUR 1.00 (0.59)Cash flow from operating activities per share was EUR 1.95 (0.57)Several key milestones reached with ODM-212 development assetFDA approval for Animal Health division's Tessie® Januar

Orion Oyj Class AJuly 17, 202614 min read

About this update from Orion Oyj Class A

ORION CORPORATION  HALF-YEAR FINANCIAL REPORT 1–6/2026 17 JULY 2026 at 12:00 EEST Orion Group Half-Year Financial Report January–June 2026 April–June 2026 Highlights January–June 2026 Highlights Key figures President and CEO Liisa Hurme: Strong quarter marked by accelerating growth and improved profitability

View stock analysis, news, and events for Orion Oyj Class A

Orion Group Half-Year Financial Report January–June 2026

About this update from Orion Oyj Class A

More from Orion Oyj Class A

Orion publishes Half-Year Report for January–June 2026 and holds a webcast on 17 July 2026

Orion Pharma’s ODM-212 Granted Orphan Designation for the Treatment of Malignant Mesothelioma by the European Commission